Case study:  The critical role of rapid CYP2C19 pharmacogenetic testing in enabling NHS reform ambitions.

** In association with Genedrive**

The NHS faces the challenge of reducing waiting lists, cutting costs, and improving outcomes, with prevention central to Government ambition. Pharmacogenetic testing offers a practical route to achieving this. genedrive’s Rapid CYP2C19 test, CE-IVD approved and NICE-recommended, provides near-patient genetic insights to guide more effective prescribing and reduce the risk of clopidogrel resistance, present in up to 56% of patients. In stroke care, widespread adoption could prevent 2,855 recurrent strokes, release 62,500 hospital bed days, and deliver £160 million in annual value. This session explores how rapid testing can improve outcomes and support NHS reform.